SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

被引：0
|
作者：
Curioni-Fontecedro, A. [1 ]
Holer, L. [2 ]
Frueh, M. [3 ]
Weindler, S. [4 ]
Konig, D. [5 ]
Addeo, A. [6 ]
Britschgi, C. [7 ]
Rigutto, A. [8 ,9 ]
Waibel, C. [10 ]
Bettini, A. [11 ]
Cerciello, F. W. F. [12 ]
Hiltbrunner, S. [9 ,13 ]
Nguyen, D. L. [14 ]
Zellweger, C. [15 ]
Musilova, J. [16 ]
Von Moos, R. A. F. [17 ]
Joerger, M. [18 ]
机构：
[1] Univ Zurich Hosp, Dept Oncol, Cantonal Hosp Fribourg, Fribourg, Switzerland
[2] SAKK Swiss Grp Clin Canc Res, Bern, Switzerland
[3] Kantonsspital St Gallen, Dept Oncol, St Gallen, Switzerland
[4] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[5] Univ Basel Hosp, Dept Med Oncol, Basel, Switzerland
[6] HUG Hop Univ Geneve, Dept Oncol, Geneva, Switzerland
[7] USZ Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland
[8] Univ Zurich, Fac Sci & Med, Dept Med Surg Specialties, Zurich, Switzerland
[9] Univ Fribourg, Fribourg, Switzerland
[10] Kantonsspital Baden, Med Oncol, Baden, Switzerland
[11] HFR Hop Cantonal, Med Oncol, Fribourg, Switzerland
[12] Univ Klin Med Onkol, Dept Med Oncol, Inselspital, Bern, Switzerland
[13] Univ Zurich Hosp, Fac Sci & Med, Zurich, Switzerland
[14] Stadtsp Zurich Triemli, Dept Radiol & Nucl Med, Zurich, Switzerland
[15] USZ Univ Hosp Zurich, Dept Radiol, Inst Diagnost & Intervent Radiol, Zurich, Switzerland
[16] SAKK Swiss Grp Clin Canc Res, Dept Stat, Bern, Switzerland
[17] KSGR Kantonsspital Graubunden, Dept Hematol Oncol, Chur, Switzerland
[18] Kantonsspital St Gallen, Med Oncol & Hematol Dept, St Gallen, Switzerland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1412P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
    Yousuke Nakai
    Hiroyuki Isayama
    Hideaki Ijichi
    Takashi Sasaki
    Naminatsu Takahara
    Yukiko Ito
    Saburo Matsubara
    Rie Uchino
    Hiroshi Yagioka
    Toshihiko Arizumi
    Tsuyoshi Hamada
    Koji Miyabayashi
    Suguru Mizuno
    Keisuke Yamamoto
    Hirofumi Kogure
    Natsuyo Yamamoto
    Kenji Hirano
    Naoki Sasahira
    Keisuke Tateishi
    Minoru Tada
    Kazuhiko Koike
    Investigational New Drugs, 2013, 31 : 1294 - 1299
  • [22] Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC).
    Haider, K
    Kornek, G
    Kwasny, W
    Depisch, D
    Payrits, T
    Scheithauer, W
    Lang, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 51S - 51S
  • [23] EXIBIT:: An international multicenter phase II trial of gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer.
    André, T.
    Reyes-Vidal, J. M.
    Fartoux, L.
    Ross, P.
    Leslie, M.
    Rosmorduc, O.
    Clemens, M. R.
    Louvet, C.
    Perez, N.
    Scheithauer, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 211S - 211S
  • [24] A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
    Nakai, Yousuke
    Isayama, Hiroyuki
    Ijichi, Hideaki
    Sasaki, Takashi
    Takahara, Naminatsu
    Ito, Yukiko
    Matsubara, Saburo
    Uchino, Rie
    Yagioka, Hiroshi
    Arizumi, Toshihiko
    Hamada, Tsuyoshi
    Miyabayashi, Koji
    Mizuno, Suguru
    Yamamoto, Keisuke
    Kogure, Hirofumi
    Yamamoto, Natsuyo
    Hirano, Kenji
    Sasahira, Naoki
    Tateishi, Keisuke
    Tada, Minoru
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1294 - 1299
  • [25] Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review
    Wagner, Gernot
    Stollenwerk, Hannah Karolina
    Klerings, Irma
    Pecherstorfer, Martin
    Gartlehner, Gerald
    Singer, Josef
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [26] Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study
    Zhang, Jian
    Wang, Hao
    Zhou, Jundong
    Zou, Zhonghua
    Tan, Jie
    Shi, Jianping
    Yang, Hui
    Xue, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial
    Ni, J.
    Wu, L.
    Ai, X.
    Dong, X.
    Chu, Q.
    Han, C.
    Zhu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S887 - S887
  • [28] Combination gemcitabine and oxaliplatin for advanced non small cell lung cancer (NSCLC): An Australian multicenter randomized phase II sequencing trial.
    Broad, A
    Links, M
    Rosenthal, MA
    Mitchell, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 681S - 681S
  • [29] Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial.
    Socinski, M. A.
    Novello, S.
    Sanchez, J. M.
    Brahmer, J. A.
    Govindan, R.
    Belani, C. P.
    Atkins, J. N.
    Gillenwater, H. H.
    Palleres, C.
    Chao, R. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 364S - 364S
  • [30] Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial
    Pallis, A. G.
    Christofillakis, Ch.
    Tselepatiotis, E.
    Agelaki, S.
    Vamvakas, L.
    Souglakos, J.
    Vardakis, N.
    Kalykaki, A.
    Kotsakis, A.
    Argiraki, A.
    Mavroudis, D.
    Georgoulias, V.
    LUNG CANCER, 2007, 55 (01) : 101 - 107
12345